ATE307607T1 - Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern - Google Patents

Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern

Info

Publication number
ATE307607T1
ATE307607T1 AT03016996T AT03016996T ATE307607T1 AT E307607 T1 ATE307607 T1 AT E307607T1 AT 03016996 T AT03016996 T AT 03016996T AT 03016996 T AT03016996 T AT 03016996T AT E307607 T1 ATE307607 T1 AT E307607T1
Authority
AT
Austria
Prior art keywords
cattles
treatment
respiratory disease
polynucleotide vaccine
vaccine
Prior art date
Application number
AT03016996T
Other languages
German (de)
English (en)
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Philippe Baudu
Michel Riviere
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of ATE307607T1 publication Critical patent/ATE307607T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/813—Viral vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03016996T 1996-07-19 1997-07-16 Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern ATE307607T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609403A FR2751229B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins

Publications (1)

Publication Number Publication Date
ATE307607T1 true ATE307607T1 (de) 2005-11-15

Family

ID=9494497

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03016996T ATE307607T1 (de) 1996-07-19 1997-07-16 Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
AT97934578T ATE253376T1 (de) 1996-07-19 1997-07-16 Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97934578T ATE253376T1 (de) 1996-07-19 1997-07-16 Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern

Country Status (28)

Country Link
US (2) US6376473B1 (OSRAM)
EP (2) EP1382348B1 (OSRAM)
JP (1) JP2000516200A (OSRAM)
AP (1) AP9701044A0 (OSRAM)
AR (1) AR007862A1 (OSRAM)
AT (2) ATE307607T1 (OSRAM)
AU (1) AU734442B2 (OSRAM)
BR (1) BR9710506A (OSRAM)
CA (1) CA2260855C (OSRAM)
CO (1) CO4700306A1 (OSRAM)
CZ (2) CZ298915B6 (OSRAM)
DE (2) DE69734483T2 (OSRAM)
DK (2) DK1382348T3 (OSRAM)
ES (2) ES2210548T3 (OSRAM)
FR (1) FR2751229B1 (OSRAM)
HR (1) HRP970383A2 (OSRAM)
HU (2) HU225169B1 (OSRAM)
ID (1) ID19513A (OSRAM)
IL (2) IL127703A0 (OSRAM)
MA (1) MA24269A1 (OSRAM)
NZ (4) NZ508939A (OSRAM)
PE (1) PE84699A1 (OSRAM)
PL (1) PL190122B1 (OSRAM)
PT (1) PT912194E (OSRAM)
RU (1) RU2305560C2 (OSRAM)
UA (1) UA70914C2 (OSRAM)
WO (1) WO1998003200A2 (OSRAM)
ZA (1) ZA976283B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
ATE510928T1 (de) 2004-02-19 2011-06-15 Univ Alberta Leptinpromotor-polymorphismen und verwendungen davon
HRP20100314T1 (hr) 2005-04-25 2010-08-31 Merial Ltd. Cjepivo protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 ｄｎａ 플라스미드
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
IN2012DN06589A (OSRAM) 2010-01-19 2015-10-23 Harvard College
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CA2792118C (en) 2010-03-12 2022-07-12 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
MX344103B (es) 2010-08-31 2016-12-05 Merial Ltd Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
AR084358A1 (es) * 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
WO2012166450A1 (en) 2011-05-27 2012-12-06 Merial Limited Genetic vaccines against hendra virus and nipah virus
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US20130177591A1 (en) 2012-01-10 2013-07-11 Merial Limited Lipid Based Adjuvants for DNA Plasmids
CA2864106C (en) 2012-02-14 2017-10-17 Merial Limited Rotavirus subunit vaccines and methods of making and use thereof
JP6260972B2 (ja) 2012-02-14 2018-01-17 メリアル インコーポレイテッド 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2861248B1 (en) 2012-06-13 2017-11-15 Merial, Inc. Reassortant btv and ahsv vaccines
IN2015DN01448A (OSRAM) 2012-08-01 2015-07-03 Bavarian Nordic As
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3848045A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR105482A1 (es) 2015-06-23 2017-10-11 Merial Inc Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
MA42653A (fr) 2015-08-20 2018-06-27 Merial Inc Vaccins recombinants contre le fcv et utilisations de ceux-ci
MA43016A (fr) 2015-09-29 2018-08-08 Merial Inc Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
NZ743236A (en) 2015-11-23 2019-12-20 Boehringer Ingelheim Animal Health Usa Inc Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN109021081B (zh) * 2018-08-10 2019-06-04 山东大学 一种牛病毒性腹泻病毒样颗粒及其构建方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0413695B1 (en) * 1988-04-22 1994-05-04 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3.
WO1992001471A1 (en) * 1990-07-24 1992-02-06 The Uab Research Foundation Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5541102A (en) * 1994-09-02 1996-07-30 Board Of Regents, University Of Nebraska-Lincoln Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060457A (en) 1996-06-20 2000-05-09 Universite De Montreal DNA plasmid vaccine for immunization of animals against BVDV
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
JP5566663B2 (ja) * 2009-11-09 2014-08-06 三菱重工業株式会社 多翼遠心ファンおよびそれを用いた空気調和機

Also Published As

Publication number Publication date
IL127703A (en) 2006-12-31
WO1998003200A2 (fr) 1998-01-29
HUP9902791A3 (en) 2000-03-28
AU3773597A (en) 1998-02-10
RU2002132831A (ru) 2005-01-20
DE69734483D1 (de) 2005-12-01
EP1382348A3 (fr) 2004-01-28
DE69725988T2 (de) 2004-11-11
NZ508939A (en) 2002-04-26
EP0912194B1 (fr) 2003-11-05
HRP970383A2 (en) 1998-10-31
CA2260855A1 (en) 1998-01-29
HU228353B1 (en) 2013-03-28
DE69725988D1 (de) 2003-12-11
NZ333751A (en) 2001-03-30
CO4700306A1 (es) 1998-12-29
UA70914C2 (uk) 2004-11-15
PT912194E (pt) 2004-03-31
PL190122B1 (pl) 2005-11-30
ES2254833T3 (es) 2006-06-16
DE69734483T2 (de) 2006-07-20
AU734442B2 (en) 2001-06-14
CZ17599A3 (cs) 1999-06-16
NZ517686A (en) 2003-01-31
AP9701044A0 (en) 1997-07-31
US20020160018A1 (en) 2002-10-31
US6376473B1 (en) 2002-04-23
AR007862A1 (es) 1999-11-24
ATE253376T1 (de) 2003-11-15
CZ298898B6 (cs) 2008-03-05
NZ508940A (en) 2002-09-27
FR2751229A1 (fr) 1998-01-23
MA24269A1 (fr) 1998-04-01
DK0912194T3 (da) 2004-03-15
CZ298915B6 (cs) 2008-03-12
PE84699A1 (es) 1999-11-28
BR9710506A (pt) 1999-08-17
US6818628B2 (en) 2004-11-16
IL127703A0 (en) 1999-10-28
HUP9902791A2 (hu) 1999-12-28
WO1998003200A3 (fr) 1998-02-26
PL331236A1 (en) 1999-07-05
RU2305560C2 (ru) 2007-09-10
EP1382348B1 (fr) 2005-10-26
FR2751229B1 (fr) 1998-11-27
ID19513A (id) 1998-07-16
JP2000516200A (ja) 2000-12-05
ZA976283B (en) 1999-01-19
EP1382348A2 (fr) 2004-01-21
ES2210548T3 (es) 2004-07-01
DK1382348T3 (da) 2006-03-13
CA2260855C (en) 2012-01-03
HU0500910D0 (en) 2005-11-28
HU225169B1 (en) 2006-07-28
EP0912194A2 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
ATE307607T1 (de) Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
DE59712045D1 (de) Vorrichtung zur behandlung des herzens
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69734778D1 (de) Polynukleotid-impfstoffformulierung gegen pferdekrankheiten
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DK0912743T3 (da) Polynukleotidvaccinepræparat til behandling af luftvejs- og reproduktionssygdomme hos svin
DE69731309D1 (de) Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69737590D1 (de) Wasserabsorbierendes produkt und methode zu seiner herstellung
FR2718037B1 (fr) Appareil de traitement de tumeur.
GB2319725B (en) Extracting particles produced by the treating of human or animal nails
DE69506019D1 (de) Vorrichtung zur Behandlung von Schmerz
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE59707096D1 (de) Haarbehandlungsmittel zur Festigung der Haare
EP1109929A4 (en) METHODS OF DIAGNOSING RENAL SALT LOSS SYNDROME AND ALZHEIMER'S DISEASE AND METHODS OF TREATMENT THEREOF
DE69519602D1 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1382348

Country of ref document: EP